PMID- 25953493
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20181113
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 15
DP  - 2015 May 8
TI  - Long-term experience of hyperbaric oxygen therapy for refractory radio- or 
      chemotherapy-induced haemorrhagic cystitis.
PG  - 38
LID - 10.1186/s12894-015-0035-4 [doi]
LID - 38
AB  - BACKGROUND: Radiotherapy and cyclophosphamide-induced haemorrhagic cystitis are 
      rare but severe complications occurring in 3-6% of patients. Hyperbaric oxygen 
      treatment (HBOT) has been demonstrated to be an effective treatment for 
      haematuria not responding to conventional management. Only very few data exist 
      for long-term follow-up after HBOT. METHODS: We retrospectively reviewed 15 
      patients referred for HBOT for haemorrhagic cystitis (HC). HBOT was performed for 
      130 min/day at a pressure of 2.4 atmospheres. We evaluated patient demographics, 
      type of radio- and chemotherapy and characteristics of haematuria. The effect of 
      HBOT was defined as complete or partial resolution of hematuria according to the 
      RTOG/EORTC grade and Gray score. RESULTS: A total of 15 patients (12 after 
      radiotherapy, two after chemotherapy and one patient with a combination of both) 
      were treated with a median of 34 HBO treatments. Radiotherapy patients received 
      primary, adjuvant, salvage and HDR radiotherapy (60 - 78 Gy) for prostate, colon 
      or cervical cancer. The patient with combination therapy and both of the 
      chemotherapy patients were treated with cyclophosphamide. First episodes of 
      haematuria occurred at a median of 48 months after completion of initial therapy. 
      The first HBOT was performed at a median of 11 months after the first episode of 
      hematuria. After a median of a 68-month follow-up after HBOT, 80% experienced a 
      complete resolution and two patients suffered a singular new minor haematuria (p 
      < 0.00001). A salvage-cystectomy was necessary in one patient. No adverse effects 
      were documented. CONCLUSIONS: Our experience indicate that HBOT is a safe and 
      effective therapeutic option for treatment-resistant radiogenic and 
      chemotherapy-induced haemorrhagic cystitis. For a better evaluation prospective 
      clinical trials are required.
FAU - Degener, Stephan
AU  - Degener S
AD  - Department of Urology, HELIOS Medical Center Wuppertal, University of 
      Witten/Herdecke, Heusnerstrasse 40, 42283, Wuppertal, Germany. 
      stephan.degener@helios-kliniken.de.
FAU - Pohle, Alexander
AU  - Pohle A
AD  - Department of Urology, Medical Center Leverkusen, Am Gesundheitspark 11, 51375, 
      Leverkusen, Germany. alexander.pohle@klinikum-lev.de.
FAU - Strelow, Hartmut
AU  - Strelow H
AD  - Institute of Hyperbaric Oxygen (HBO), University Hospital Dusseldorf, 
      Moorenstrasse 5, 40225, Dusseldorf, Germany. strelow@med.uni-duesseldorf.de.
FAU - Mathers, Michael J
AU  - Mathers MJ
AD  - Urological Ambulatory PandaMED, Alleestrasse 105-107, 42853, Remscheid, Germany. 
      irtima@t-online.de.
FAU - Zumbe, Jurgen
AU  - Zumbe J
AD  - Department of Urology, Medical Center Leverkusen, Am Gesundheitspark 11, 51375, 
      Leverkusen, Germany. juergen.zumbe@klinikum-lev.de.
FAU - Roth, Stephan
AU  - Roth S
AD  - Department of Urology, HELIOS Medical Center Wuppertal, University of 
      Witten/Herdecke, Heusnerstrasse 40, 42283, Wuppertal, Germany. 
      stephan.roth@helios-kliniken.de.
FAU - Brandt, Alexander S
AU  - Brandt AS
AD  - Department of Urology, HELIOS Medical Center Wuppertal, University of 
      Witten/Herdecke, Heusnerstrasse 40, 42283, Wuppertal, Germany. 
      alexander-sascha.brandt@helios-kliniken.de.
LA  - eng
PT  - Journal Article
DEP - 20150508
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
CIN - J Urol. 2016 Nov;196(5):1456. PMID: 27751457
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Chemoradiotherapy/*adverse effects
MH  - Cohort Studies
MH  - Cyclophosphamide/adverse effects/therapeutic use
MH  - Cystitis/etiology/physiopathology/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hematuria/etiology/physiopathology/*therapy
MH  - Humans
MH  - Hyperbaric Oxygenation/*methods
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC4423090
EDAT- 2015/05/09 06:00
MHDA- 2016/04/19 06:00
PMCR- 2015/05/08
CRDT- 2015/05/09 06:00
PHST- 2015/01/09 00:00 [received]
PHST- 2015/04/22 00:00 [accepted]
PHST- 2015/05/09 06:00 [entrez]
PHST- 2015/05/09 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
PHST- 2015/05/08 00:00 [pmc-release]
AID - 10.1186/s12894-015-0035-4 [pii]
AID - 35 [pii]
AID - 10.1186/s12894-015-0035-4 [doi]
PST - epublish
SO  - BMC Urol. 2015 May 8;15:38. doi: 10.1186/s12894-015-0035-4.